Evidence for tissue selectivity of the synthetic androgen 7 alpha-methyl-19-nortestosterone in hypogonadal men

The Journal of Clinical Endocrinology and Metabolism
Richard A AndersonKalyan Sundaram

Abstract

The potent synthetic androgen 7 alpha-methyl-19-nortestosterone (MENT) is resistant to 5 alpha-reductase but is a substrate for aromatase. It may therefore offer selective sparing of the prostate gland while supporting other androgen-dependent tissues. MENT acetate implants were administered for 24 wk to 16 hypogonadal men, randomly allocated to 1 or 2 implants (groups I and II, respectively; releasing approximately 400 microg/d x implant). Hemoglobin concentration and hematocrit were maintained during MENT treatment. Prostate volume fell in group I and to a small, but statistically nonsignificant, degree in group II; the level of prostate-specific antigen fell significantly in both. Lumbar spine bone mineral density decreased in both groups. Sexual behavior and erectile function declined in group I, but were maintained in group II. Thus, overall, one MENT implant appeared to provide subphysiological androgen replacement. The 2-implant dose of MENT was able to maintain most androgen-dependent functions, except bone mass, and there was evidence to support selective sparing of the prostate gland. These results demonstrate for the first time in humans the selectivity of MENT in tissues dependent on 5 alpha-reductase. In addition, ...Continue Reading

Citations

Jan 5, 2011·Asian Journal of Andrology·Mara Y Roth, Stephanie T Page
Dec 7, 2006·Nature Clinical Practice. Urology·Upendram Srinivas-Shankar, Frederick C W Wu
Feb 1, 2013·Brain : a Journal of Neurology·Rashad HussainM Said Ghandour
Nov 9, 2011·Reproduction : the Official Journal of the Society for the Study of Fertility·Rocío García-BecerraFernando Larrea
Sep 1, 2005·Women's Health·Ra Anderson, Mj Walton
May 23, 2012·Expert Opinion on Emerging Drugs·Giovanni CoronaMario Maggi
Nov 16, 2007·Expert Opinion on Pharmacotherapy·Daniel EdelsteinShehzad Basaria
Oct 27, 2006·Expert Opinion on Emerging Drugs·Daniel EdelsteinShehzad Basaria
Aug 28, 2004·Expert Opinion on Investigational Drugs·Melanie Walton, Richard A Anderson
Jul 19, 2008·International Journal of Andrology·Patricia MendozaEnrique A Castellón
May 10, 2006·The Journal of Sexual Medicine·Abdulmaged M Traish, André T Guay
May 3, 2007·Obstetrics and Gynecology Clinics of North America·David Turok
May 28, 2004·Clinical Endocrinology·Carolyn A Allan, Robert I McLachlan
Dec 14, 2005·Clinical Endocrinology·Christian MeierMarkus J Seibel
Aug 22, 2006·Clinical Endocrinology·Eberhard Nieschlag
Mar 1, 2005·Trends in Endocrinology and Metabolism : TEM·David J Handelsman, Peter Y Liu
Aug 10, 2005·Expert Opinion on Pharmacotherapy·Ammar QoubaitaryChristina Wang
Aug 24, 2016·Expert Opinion on Emerging Drugs·Aydogan Aydogdu, Ronald S Swerdloff
Mar 7, 2009·Medicina clínica·Oscar Moreno-PérezJoaquín Portilla
Nov 1, 2008·Contraception·Diana Blithe
Apr 1, 2005·The Aging Male : the Official Journal of the International Society for the Study of the Aging Male·A Vermeulen
Sep 28, 2005·Treatments in Endocrinology·Emily Darby, Bradley D Anawalt
May 20, 2005·Endocrine Reviews·Jean M Kaufman, Alex Vermeulen
Apr 7, 2006·Human Reproduction Update·Kati L Matthiesson, Robert I McLachlan
Oct 11, 2015·Andrology·M Y RothW J Bremner
Sep 21, 2019·BMJ Sexual & Reproductive Health·John Joseph Reynolds-Wright, Richard Anderson
Dec 2, 2004·Expert Opinion on Emerging Drugs·Paul B Cornia, Bradley D Anawalt
Oct 5, 2006·British Journal of Hospital Medicine·Andrew Solomon, Pierre Bouloux
Jan 1, 2006·Expert Review of Endocrinology & Metabolism·Melanie J Walton, Richard A A Anderson
Oct 24, 2020·Journal of the Endocrine Society·Vittorio Emanuele BianchiAntonio Torsello

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.